Table 1A.
Basic information of each document
| Number | Author | years | Country of publication | Sample size | Gender (Male/female) | Age (years) | Intervention program | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||||||
| A | B | A | B | A | B | A | B | ||||
| 1 | J.J. Gorgojo-Martínez | 2016 | Spain | 104 | 109 | 65/59 | 49/55 | 59.1±10.7 | 59.7±10.8 | SGLT-2 | SGLT-2+GLP-1 |
| 2 | João Sérgio Neves | 2023 | Portugal | 8887 | 575 | 6133/2754 | 435/140 | 64.2±8.7 | 62.9±8.2 | GLP-1 | SGLT-2+GLP-1 |
| 3 | Rafaele Marfella | 2024 | Italy | 99 | 214 | 64/35 | 131/83 | 68 (63-73) | 70 (64-70) | SGLT-2 | SGLT-2+GLP-1 |
| 4 | Jingpu Wang | 2023 | China | 63 | 62 | 40/23 | 30/32 | 57.5±9.9 | 56.2±10.2 | DAPA 10 mg/day + placebo | SGLT-2 Dagliprazin (DAPA) 10 mg/day +GLP-1 Exenatide (ExQW) 2 mg/week |
| 5 | Yan Pi | 2022 | China | 40 | 40 | 21/19 | 23/17 | 52.12±10.2 | 51.23±10.4 | Liraglutide (GLP-1 receptor agonist, initial dose 0.6 mg/day, increased to 1.8 mg/day after one week of treatment) | Liraglutide (GLP-1 receptor agonist, initial dose 0.6 mg/day, increased to 1.8 mg/day after one week of treatment) + Dagliprazin (SGLT-2 inhibitor, 10 mg/day orally) |
| 6 | Lin, Yu-Hao | 2024 | China | 35 | 35 | / | / | / | / | SGLT-2 | SGLT-2+GLP-1 |
| 7 | Toru Ishikawa | 2024 | Japan | 15 | 15 | 5/10 | 5/10 | 67.3 (61.9-74.5) | 67.3 (61.9-74.5) | SGLT-2 | SGLT-2+GLP-1 |
| 8 | Liv Vernstrøm MD | 2024 | Denmark | 30 | 30 | 22/8 | 25/5 | 70±7 | 70±7 | SGLT-2 (Engalizin) | SGLT-2 (Englaglizin) +GLP-1 (Semaglutide) |
| 9 | Konstantinos Katogiannis | 2024 | Greece | 50 | 50 | 37/13 | 38/12 | 58.1±8.8 | 59.3±8.9 | SGLT-2 (Engalizin) | SGLT-2+GLP-1 |
| 10 | Francesco Giorgino | 2024 | Italy | 746 | 219 | 379/267 | 136/83 | 62.0±9.9 | 60.5±10.7 | GLP-1 | SGLT-2+GLP-1 |
| 11 | Suvanjaa Sivalingam | 2024 | Denmark | 30 | 30 | 23/7 | 24/6 | 69.4±9.1 | 70.5±6.8 | placebo | SGLT-2+GLP-1 (Semaglutide) |
| 12 | Annemarie B | 2023 | Netherlands | 20 | 20 | 4/16 | 16/4 | 70.5±5.1 | 70.5±5.1 | SGLT-2 (Dagliazine 10 mg/day) | SGLT-2 (Dagaglizin 10 mg/day) +GLP-1 (exenatide 2 mg/week) |
| 13 | Søren Gullaksen | 2023 | Denmark | 30 | 30 | 22/8 | 25/5 | 70.4±6.6 | 69.5±6.8 | SGLT-2 (Engalizin) | SGLT-2 (Englaglizin) +GLP-1 (Semaglutide) |
| 14 | Søren Gullaksen | 2024 | Denmark | 20 | 20 | 14/6 | 17/3 | 69.6±6.0 | 67.9±6.2 | SGLT-2 (10 mg Empaglizin) | SGLT-2 (10 mg Empaglizin) +GLP-1 (1.0 mg Semaglutide) |
| 15 | Juan P Frias | 2023 | America | 30 | 31 | 23/17 | 18/13 | 57±10 | 62±7 | SGLT-2 (once a week subcutaneous injection of caglutide 2.4 mg) | SGLT-2 (once a week subcutaneous injection of caglutide 2.4 mg) +GLP-1 (Semaglutide 2.4 mg) |